Detalhe da pesquisa
1.
The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer.
Sci Rep
; 12(1): 293, 2022 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34997154
2.
The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer.
Cancers (Basel)
; 13(19)2021 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638488
3.
Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice.
Sci Rep
; 11(1): 1234, 2021 01 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33441637
4.
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
Sci Rep
; 10(1): 22244, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335263
5.
A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.
Theranostics
; 9(21): 6224-6238, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31534547
6.
Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models.
NPJ Breast Cancer
; 5: 39, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31700995
7.
Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention.
Cancer Prev Res (Phila)
; 12(4): 211-224, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30760500
8.
Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762.
Cancer Prev Res (Phila)
; 11(3): 143-156, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29246957